For cancer patients with suspected PE, how should the HYDRA trial--which proposes using the YEARS algorithm is as safe as a CTPA-only approach--change the diagnostic workup?
The HYDRA trial avoided CTPA in about 1 in 5 patients using the YEARS algorithm. Is that enough efficiency gain to change your diagnostic approach given the consequences of missed PE in active cancer? Which patients should still go directly to CTPA despite meeting YEARS rule-out criteria?
Community PollStarted
For patients with active cancer and suspected PE, will the HYDRA trial change your diagnostic practice?
39 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Hematology · Medical University of South Carolina
Answered on
The YEARS algorithm was originally developed to determine which adults with suspected pulmonary embolism (PE) can safely avoid computed tomographic pulmonary angiography (CTPA). It uses three criteria — clinical signs of deep-vein thrombosis, hemoptysis, and PE judged the most likely diagnosis — com...
Join for free or sign in to see the full answer